Allogene Therapeutics (ALLO)

• Market cap: $257M
• 1 day: 0.00%
• 5 days: 9.43%
• 1 month: -21.09%
• 3 months: 7.41%
• 6 months: -43.14%
• Year to date: -47.27%
• 1 year: -58.57%
• 5 years: -96.66%
• 10 years: -95.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Employees: 361

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

85% more call options, than puts

Call options by funds: $139K | Put options by funds: $75K

9% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

6.85% less ownership

Funds ownership: 90.63% [Q1] → 83.78% (-6.85%) [Q2]

8% less funds holding

Funds holding: 169 [Q1] → 155 (-14) [Q2]

31% less capital invested

Capital invested by funds: $301M [Q1] → $207M (-$94M) [Q2]

37% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 27